the full article is fascinating
It suggests it will be best used in her2+ early breast cancer patients with micro or macroscopic lymph node involvement. A company has been formed and Phase I trials in several solid tumors is ongoing (none breast cancer, however). FDA approval for use vs Wilsons disease is pending.
|